<!DOCTYPE html>
<html lang="en-US">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <title>细胞因子吸要废了吗？ | SSCC</title>
    <meta name="generator" content="VuePress 1.9.5">
    <link rel="icon" href="/img/favicon.ico">
    <a rel="noreferrer" target="_blank"></a>
    <meta name="description" content="SSCC交流平台，供医护学习、讨论、积累CCM知识">
    <meta name="keywords" content="重症医学,血流,指南,critical care medicine,">
    <meta name="baidu-site-verification" content="7F55weZDDc">
    <meta name="theme-color" content="#11a8cd">
    <meta name="referrer" content="no-referrer">
    
    <link rel="preload" href="/assets/css/0.styles.bc9496d9.css" as="style"><link rel="preload" href="/assets/js/app.1f0360bc.js" as="script"><link rel="preload" href="/assets/js/5.860c287a.js" as="script"><link rel="preload" href="/assets/js/36.7a8a83c9.js" as="script"><link rel="prefetch" href="/assets/js/10.c5177d57.js"><link rel="prefetch" href="/assets/js/100.64a8c682.js"><link rel="prefetch" href="/assets/js/101.81c4801b.js"><link rel="prefetch" href="/assets/js/102.d1196a9e.js"><link rel="prefetch" href="/assets/js/103.40639d12.js"><link rel="prefetch" href="/assets/js/104.ab22a3b3.js"><link rel="prefetch" href="/assets/js/105.7f44c263.js"><link rel="prefetch" href="/assets/js/106.5199c19e.js"><link rel="prefetch" href="/assets/js/107.893f0c72.js"><link rel="prefetch" href="/assets/js/108.683ab44f.js"><link rel="prefetch" href="/assets/js/109.2fa09ff0.js"><link rel="prefetch" href="/assets/js/11.0354f2cd.js"><link rel="prefetch" href="/assets/js/110.03021847.js"><link rel="prefetch" href="/assets/js/111.61e4e1d4.js"><link rel="prefetch" href="/assets/js/112.4c8a2b39.js"><link rel="prefetch" href="/assets/js/113.1cbdb6a0.js"><link rel="prefetch" href="/assets/js/114.543eaac6.js"><link rel="prefetch" href="/assets/js/115.5d44cfc7.js"><link rel="prefetch" href="/assets/js/116.0ca3fd53.js"><link rel="prefetch" href="/assets/js/117.d9344be6.js"><link rel="prefetch" href="/assets/js/118.49f13a5b.js"><link rel="prefetch" href="/assets/js/119.07b4c8c9.js"><link rel="prefetch" href="/assets/js/12.cb44ee5e.js"><link rel="prefetch" href="/assets/js/120.f1ac1a2c.js"><link rel="prefetch" href="/assets/js/121.f424e7a0.js"><link rel="prefetch" href="/assets/js/122.8b191552.js"><link rel="prefetch" href="/assets/js/123.40a12f37.js"><link rel="prefetch" href="/assets/js/124.835a8ecb.js"><link rel="prefetch" href="/assets/js/125.15a04827.js"><link rel="prefetch" href="/assets/js/126.b7c586bf.js"><link rel="prefetch" href="/assets/js/127.37e4f2e3.js"><link rel="prefetch" href="/assets/js/128.32a47b69.js"><link rel="prefetch" href="/assets/js/129.0dc78db2.js"><link rel="prefetch" href="/assets/js/13.302bf743.js"><link rel="prefetch" href="/assets/js/130.7e3a2ff5.js"><link rel="prefetch" href="/assets/js/131.8044dcc0.js"><link rel="prefetch" href="/assets/js/132.c503d1ef.js"><link rel="prefetch" href="/assets/js/133.4412520a.js"><link rel="prefetch" href="/assets/js/134.3ef5b397.js"><link rel="prefetch" href="/assets/js/135.4ff7c37b.js"><link rel="prefetch" href="/assets/js/136.76e1c2c8.js"><link rel="prefetch" href="/assets/js/137.884a5437.js"><link rel="prefetch" href="/assets/js/138.812f3dc1.js"><link rel="prefetch" href="/assets/js/139.c268486a.js"><link rel="prefetch" href="/assets/js/14.1413f2d1.js"><link rel="prefetch" href="/assets/js/140.9f8db6b1.js"><link rel="prefetch" href="/assets/js/141.d8f612a6.js"><link rel="prefetch" href="/assets/js/142.59bcd0c5.js"><link rel="prefetch" href="/assets/js/143.17dbc5e3.js"><link rel="prefetch" href="/assets/js/15.159e8780.js"><link rel="prefetch" href="/assets/js/16.4926815d.js"><link rel="prefetch" href="/assets/js/17.a5c9c14e.js"><link rel="prefetch" href="/assets/js/18.ebad2ced.js"><link rel="prefetch" href="/assets/js/19.18c0b7ec.js"><link rel="prefetch" href="/assets/js/20.6dfb129b.js"><link rel="prefetch" href="/assets/js/21.349dbee2.js"><link rel="prefetch" href="/assets/js/22.6e61a3df.js"><link rel="prefetch" href="/assets/js/23.05ab5c73.js"><link rel="prefetch" href="/assets/js/24.d700d1eb.js"><link rel="prefetch" href="/assets/js/25.1f2a726d.js"><link rel="prefetch" href="/assets/js/26.e3f0ed1b.js"><link rel="prefetch" href="/assets/js/27.8bc9b8bf.js"><link rel="prefetch" href="/assets/js/28.3cdc0fa2.js"><link rel="prefetch" href="/assets/js/29.9ca275f5.js"><link rel="prefetch" href="/assets/js/30.4c2389d3.js"><link rel="prefetch" href="/assets/js/31.5d99b510.js"><link rel="prefetch" href="/assets/js/32.ed0e7857.js"><link rel="prefetch" href="/assets/js/33.cfc16a05.js"><link rel="prefetch" href="/assets/js/34.df76e264.js"><link rel="prefetch" href="/assets/js/35.5311aa84.js"><link rel="prefetch" href="/assets/js/37.239f1e47.js"><link rel="prefetch" href="/assets/js/38.b84b49c7.js"><link rel="prefetch" href="/assets/js/39.f2b6e5fb.js"><link rel="prefetch" href="/assets/js/40.3366576b.js"><link rel="prefetch" href="/assets/js/41.16d73e2a.js"><link rel="prefetch" href="/assets/js/42.ebbb8897.js"><link rel="prefetch" href="/assets/js/43.93759415.js"><link rel="prefetch" href="/assets/js/44.87fa84f6.js"><link rel="prefetch" href="/assets/js/45.93daf5e2.js"><link rel="prefetch" href="/assets/js/46.5dc58e83.js"><link rel="prefetch" href="/assets/js/47.c3cf3056.js"><link rel="prefetch" href="/assets/js/48.51fec3c1.js"><link rel="prefetch" href="/assets/js/49.1716cc82.js"><link rel="prefetch" href="/assets/js/50.7f726cff.js"><link rel="prefetch" href="/assets/js/51.f62a5d7e.js"><link rel="prefetch" href="/assets/js/52.7386a66a.js"><link rel="prefetch" href="/assets/js/53.b9b1237d.js"><link rel="prefetch" href="/assets/js/54.c77c49c7.js"><link rel="prefetch" href="/assets/js/55.31e9a094.js"><link rel="prefetch" href="/assets/js/56.a34a92c7.js"><link rel="prefetch" href="/assets/js/57.68ad4343.js"><link rel="prefetch" href="/assets/js/58.959fa8d1.js"><link rel="prefetch" href="/assets/js/59.57b5b197.js"><link rel="prefetch" href="/assets/js/6.a97594e2.js"><link rel="prefetch" href="/assets/js/60.d0b50aa9.js"><link rel="prefetch" href="/assets/js/61.2366d981.js"><link rel="prefetch" href="/assets/js/62.86258ee9.js"><link rel="prefetch" href="/assets/js/63.86a222d1.js"><link rel="prefetch" href="/assets/js/64.1600f6a5.js"><link rel="prefetch" href="/assets/js/65.6fb868a4.js"><link rel="prefetch" href="/assets/js/66.20071b81.js"><link rel="prefetch" href="/assets/js/67.8497914e.js"><link rel="prefetch" href="/assets/js/68.8a3cd332.js"><link rel="prefetch" href="/assets/js/69.76f9bd47.js"><link rel="prefetch" href="/assets/js/7.d39151bb.js"><link rel="prefetch" href="/assets/js/70.0a1e7e4b.js"><link rel="prefetch" href="/assets/js/71.9534e35c.js"><link rel="prefetch" href="/assets/js/72.257280f2.js"><link rel="prefetch" href="/assets/js/73.930e484e.js"><link rel="prefetch" href="/assets/js/74.2bc4db81.js"><link rel="prefetch" href="/assets/js/75.b8b14fe9.js"><link rel="prefetch" href="/assets/js/76.f35a30ed.js"><link rel="prefetch" href="/assets/js/77.65f8c9d3.js"><link rel="prefetch" href="/assets/js/78.05002ec8.js"><link rel="prefetch" href="/assets/js/79.d87c6025.js"><link rel="prefetch" href="/assets/js/8.3e5c898d.js"><link rel="prefetch" href="/assets/js/80.911822f8.js"><link rel="prefetch" href="/assets/js/81.f8058cee.js"><link rel="prefetch" href="/assets/js/82.ac4e4643.js"><link rel="prefetch" href="/assets/js/83.e0791eec.js"><link rel="prefetch" href="/assets/js/84.5c9b6241.js"><link rel="prefetch" href="/assets/js/85.417e8d79.js"><link rel="prefetch" href="/assets/js/86.7aa18b88.js"><link rel="prefetch" href="/assets/js/87.64f8fbdb.js"><link rel="prefetch" href="/assets/js/88.67bb9e29.js"><link rel="prefetch" href="/assets/js/89.aa2e6868.js"><link rel="prefetch" href="/assets/js/9.e133621d.js"><link rel="prefetch" href="/assets/js/90.745d4f4f.js"><link rel="prefetch" href="/assets/js/91.230dc1ff.js"><link rel="prefetch" href="/assets/js/92.1513e5ce.js"><link rel="prefetch" href="/assets/js/93.5677deee.js"><link rel="prefetch" href="/assets/js/94.15146aef.js"><link rel="prefetch" href="/assets/js/95.26737ac5.js"><link rel="prefetch" href="/assets/js/96.80ab86fc.js"><link rel="prefetch" href="/assets/js/97.bd04fa92.js"><link rel="prefetch" href="/assets/js/98.19cb716e.js"><link rel="prefetch" href="/assets/js/99.d8896e8b.js"><link rel="prefetch" href="/assets/js/vendors~flowchart.4c6539e2.js"><link rel="prefetch" href="/assets/js/vendors~mermaid.8e25ee1e.js"><link rel="prefetch" href="/assets/js/vendors~reveal.e3b05466.js">
    <link rel="stylesheet" href="/assets/css/0.styles.bc9496d9.css">
  </head>
  <body class="theme-mode-light">
    <div id="app" data-server-rendered="true"><div class="theme-container sidebar-open have-rightmenu have-body-img"><header class="navbar blur"><div title="目录" class="sidebar-button"><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" role="img" viewBox="0 0 448 512" class="icon"><path fill="currentColor" d="M436 124H12c-6.627 0-12-5.373-12-12V80c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12zm0 160H12c-6.627 0-12-5.373-12-12v-32c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12zm0 160H12c-6.627 0-12-5.373-12-12v-32c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12z"></path></svg></div> <a href="/" class="home-link router-link-active"><img src="/img/SSCC.png" alt="SSCC" class="logo"> <span class="site-name can-hide">SSCC</span></a> <div class="links"><div class="search-box"><input aria-label="Search" autocomplete="off" spellcheck="false" value=""> <!----></div> <nav class="nav-links can-hide"><div class="nav-item"><a href="/" class="nav-link">首页</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="血流" class="dropdown-title"><a href="/bloodflow/" class="link-title">血流</a> <span class="title" style="display:none;">血流</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/bloodflow/theory/" class="nav-link">血流理论</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/technology/" class="nav-link">血流技术</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/clinic/" class="nav-link">临床血流</a></li></ul></div></div><div class="nav-item"><a href="/guideline/" class="nav-link">指南</a></div><div class="nav-item"><a href="/slide/" class="nav-link">课件</a></div><div class="nav-item"><a href="/paper/" class="nav-link">文献</a></div><div class="nav-item"><a href="/theory/" class="nav-link">重症知识</a></div><div class="nav-item"><a href="/multimedia/" class="nav-link">重症技术</a></div><div class="nav-item"><a href="/story/" class="nav-link">故事</a></div><div class="nav-item"><a href="/pages/ad735e/" class="nav-link">关于</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="索引" class="dropdown-title"><a href="/archives/" class="link-title">索引</a> <span class="title" style="display:none;">索引</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/categories/" class="nav-link">分类</a></li><li class="dropdown-item"><!----> <a href="/tags/" class="nav-link">标签</a></li><li class="dropdown-item"><!----> <a href="/archives/" class="nav-link">归档</a></li></ul></div></div> <a href="https://github.com/seasideccm/seasideccm.github.io" target="_blank" rel="noopener noreferrer" class="repo-link">
    GitHub
    <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></nav></div></header> <div class="sidebar-mask"></div> <div class="sidebar-hover-trigger"></div> <aside class="sidebar" style="display:none;"><div class="blogger"><img src="/img/SSCC.png"> <div class="blogger-info"><h3>SSCC</h3> <span>只要学不死就往死里学</span></div></div> <nav class="nav-links"><div class="nav-item"><a href="/" class="nav-link">首页</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="血流" class="dropdown-title"><a href="/bloodflow/" class="link-title">血流</a> <span class="title" style="display:none;">血流</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/bloodflow/theory/" class="nav-link">血流理论</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/technology/" class="nav-link">血流技术</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/clinic/" class="nav-link">临床血流</a></li></ul></div></div><div class="nav-item"><a href="/guideline/" class="nav-link">指南</a></div><div class="nav-item"><a href="/slide/" class="nav-link">课件</a></div><div class="nav-item"><a href="/paper/" class="nav-link">文献</a></div><div class="nav-item"><a href="/theory/" class="nav-link">重症知识</a></div><div class="nav-item"><a href="/multimedia/" class="nav-link">重症技术</a></div><div class="nav-item"><a href="/story/" class="nav-link">故事</a></div><div class="nav-item"><a href="/pages/ad735e/" class="nav-link">关于</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="索引" class="dropdown-title"><a href="/archives/" class="link-title">索引</a> <span class="title" style="display:none;">索引</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/categories/" class="nav-link">分类</a></li><li class="dropdown-item"><!----> <a href="/tags/" class="nav-link">标签</a></li><li class="dropdown-item"><!----> <a href="/archives/" class="nav-link">归档</a></li></ul></div></div> <a href="https://github.com/seasideccm/seasideccm.github.io" target="_blank" rel="noopener noreferrer" class="repo-link">
    GitHub
    <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></nav>  <ul class="sidebar-links"><li><a href="/pages/51040c/" class="sidebar-link">The Burden of Brain Hypoxia and Optimal Mean Arterial Pressure in Patients With Hypoxic Ischemic Brain Injury After Cardiac Arrest</a></li><li><a href="/pages/22fc14/" class="sidebar-link">非危重成人平衡晶体与生理盐水的比较</a></li><li><a href="/pages/3ac8e3/" class="sidebar-link">重症成人平衡晶体液液与盐水的比较</a></li><li><a href="/pages/90e2bc/" class="sidebar-link">成人脓毒症机械通气应用右美托咪定还是丙泊酚镇静</a></li><li><a href="/pages/426a62/" class="sidebar-link">神经重症病人颅内感染的诊治进展</a></li><li><a href="/pages/990854/" class="sidebar-link">改变重症监护病房常规做法支持共生</a></li><li><a href="/pages/69d6ab/" class="sidebar-link">危重病期间腹泻</a></li><li><a href="/pages/8dc4c0/" class="sidebar-link">缺氧性肺血管收缩</a></li><li><a href="/pages/d30c19/" class="sidebar-link">在 COVID-19 相关呼吸衰竭患者中验证呼吸频率-氧合指数</a></li><li><a href="/pages/86dd33/" aria-current="page" class="active sidebar-link">细胞因子吸要废了吗？</a><ul class="sidebar-sub-headers"><li class="sidebar-sub-header level2"><a href="/pages/86dd33/#is-this-the-beginning-of-the-end-of-cytokine-adsorption" class="sidebar-link">Is This the Beginning of the End of Cytokine Adsorption?</a></li><li class="sidebar-sub-header level2"><a href="/pages/86dd33/#jan-t-kielstein-alexander-zarbock" class="sidebar-link">Jan T. Kielstein，Alexander Zarbock</a></li><li class="sidebar-sub-header level2"><a href="/pages/86dd33/#doi-10-1097-ccm-0000000000005509" class="sidebar-link">DOI：10.1097/CCM.0000000000005509</a></li></ul></li><li><a href="/pages/0351a7/" class="sidebar-link">危重儿童常用镇静镇痛评估方法</a></li><li><a href="/pages/6e0421/" class="sidebar-link">期刊题录 -- 2022 Current Opinion In Critical Care</a></li><li><a href="/pages/0ca457/" class="sidebar-link">期刊题录 -- 2022 Critical Care Medicine</a></li><li><a href="/pages/88bf04/" class="sidebar-link">期刊题录 -- 2022 Critical Care</a></li><li><a href="/pages/dd7af9/" class="sidebar-link">期刊题录 -- Topic of Critical Care - The New England Journal of Medicine</a></li><li><a href="/pages/ca0030/" class="sidebar-link">多重耐药和广泛耐药铜绿假单胞菌感染的流行病学与治疗</a></li><li><a href="/pages/726207/" class="sidebar-link">铜绿假单胞菌呼吸机相关性肺炎抗生素治疗8天与15天比较</a></li><li><a href="/pages/f17fb7/" class="sidebar-link">成人院外心脏骤停肾上腺素剂量、目标温度管理及神经功能与生存预后的分析</a></li><li><a href="/pages/7da312/" class="sidebar-link">重症医学新视点2022-4中文</a></li></ul> </aside> <div><main class="page"><div class="theme-vdoing-wrapper "><div class="articleInfo-wrap" data-v-75c162ac><div class="articleInfo" data-v-75c162ac><ul class="breadcrumbs" data-v-75c162ac><li data-v-75c162ac><a href="/" title="首页" class="iconfont icon-home router-link-active" data-v-75c162ac></a></li> <li data-v-75c162ac><a href="/paper/#重症文献" data-v-75c162ac>重症文献</a></li></ul> <div class="info" data-v-75c162ac><div title="作者" class="author iconfont icon-touxiang" data-v-75c162ac><a href="javascript:;" data-v-75c162ac>SSCC</a></div> <div title="创建时间" class="date iconfont icon-riqi" data-v-75c162ac><a href="javascript:;" data-v-75c162ac>2022-07-22</a></div> <!----></div></div></div> <!----> <div class="content-wrapper"><div class="right-menu-wrapper"><div class="right-menu-margin"><div class="right-menu-title">目录</div> <div class="right-menu-content"></div></div></div> <h1><img src="data:image/png;base64,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">细胞因子吸要废了吗？<!----></h1> <!----> <div class="theme-vdoing-content content__default"><h1 id="细胞因子吸附要废了吗"><a href="#细胞因子吸附要废了吗" class="header-anchor">#</a> 细胞因子吸附要废了吗？</h1> <h2 id="is-this-the-beginning-of-the-end-of-cytokine-adsorption"><a href="#is-this-the-beginning-of-the-end-of-cytokine-adsorption" class="header-anchor">#</a> Is This the Beginning of the End of Cytokine Adsorption?</h2> <h2 id="jan-t-kielstein-alexander-zarbock"><a href="#jan-t-kielstein-alexander-zarbock" class="header-anchor">#</a> Jan T. Kielstein，Alexander Zarbock</h2> <h2 id="doi-10-1097-ccm-0000000000005509"><a href="#doi-10-1097-ccm-0000000000005509" class="header-anchor">#</a> DOI：10.1097/CCM.0000000000005509</h2> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>关键词：COVID-19；细胞因子吸附；器官衰竭；血管麻痹性休克</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>KEY WORDS: COVID-19; cytokine adsorber; organ failure; vasoplegic shock</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>温斯顿・丘吉尔有句名言，“不管战略多美妙，偶尔也得看看战果。”。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>&quot; However beautiful the strategy, you should occasionally look at the results.” is a famous saying by Sir Winston Churchill.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>本期重症医学杂志刊发了 Stockmann 等人 (1) 的一项随机对照试验，执行严格，从结果看确实不错，研究细胞因子吸附治疗血管麻痹性休克 COVID-19 患者，一种关注度较高的治疗策略。(2)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In this issue of Critical Care Medicine, Stockmann et al (1) did exactly that by looking at the result of a well-performed randomized controlled trial in which they investigated an intriguing strategy, namely the use of a cytokine adsorber, in patients with COVID-19 in vasoplegic shock (2).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>与越来越流行的观点相反，在儿茶酚胺应用、病死率或其他次要结局（包括白细胞介素 - 6 (IL-6) 和 C - 反应蛋白 (CRP) 水平）上未见有任何差异。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In contrast to a growing popular belief, they neither showed any difference in the need for catecholamines nor in the mortality nor in other secondary outcomes, including interleukin (IL)-6 and C-reactive protein (CRP) levels.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>2 年来，严重急性呼吸综合征冠状病毒 2 型 (SARSCoV-2) 引起的 COVID-19 对全球健康造成了严重影响。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>For 2 years, the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) that causes the COVID-19 has had a serious impact on global health.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>特别是疫情早期的那些院外患者，尚未施行疫苗接种预防也无药物治疗（如 remdesivir 或抗体介导策略），而重症患者治疗的手段基本上也就仅限于地塞米松 (3)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Especially prior to the advent of prevention by vaccinations and pharmacologic treatment in the early phase of the disease in nonhospitalized patients like remdesivir or antibody-mediated strategies, the armamentarium for the treatment of critically ill patients was basically limited to dexamethasone (3).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>在此背景下，在病程的不同阶段针对不同的靶点体外生命支持已经用于 COVID-19 重症患者的治疗。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>On this background, extracorporeal treatments with different targets in nonidentical phases of the disease process have been explored in critically ill patients with COVID-19.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>用新鲜冰冷冻血浆行治疗性血浆置换调整优化 von Willebrand 因子 / ADAMTS-13 之比<sup class="footnote-ref"><a href="#footnote1">[1]</a><a id="footnote-ref1" class="footnote-anchor"></a></sup>。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Therapeutic plasma exchange using fresh frozen plasma is applied to optimize the von Willebrand factor/a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 ratio (4).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>在疾病的早期阶段使用病原吸附来减轻 SARSCov-2 病毒血症 (5，6)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>A pathogen adsorber is employed in the early phase of the disease to reduce SARSCov-2 viremia (5, 6).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>最常用的干预措施旨在减少 COVID-19 患者的细胞因子风暴。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Among the most frequently used interventions are aimed to reduce the cytokine storm in COVID-19 patients.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>2011 年，CytoSorb 在欧盟获得许可，作为一次性血液灌流设备，包含吸附聚合物磁珠，旨在清除分子量范围在 8-50 kDa 的物质。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In 2011, CytoSorb was licensed in the European Union as single-use hemoperfusion device containing adsorbent polymer beads designed to remove substances in the molecular weight range between 8 and 50 kDa.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>促炎和抗炎细胞因子在该范围内。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Pro- and anti-inflammatory cytokines can be found in that range.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>最近有学者提出，对紧急心脏手术的患者用 CytoSorb 清除替格瑞洛和利伐沙班 (7)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Recently removal of ticagrelor and rivaroxaban by CytoSorb has been postulated in patients undergoing emergency heart operation (7).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>2020 年 4 月 10 日，美国食品药品监督管理局批准 CytoSorb 在确诊的或即将发生呼吸衰竭的危重 COVID-19 患者可紧急使用。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>On April 10, 2020, the U.S. Food and Drug Administration granted Emergency Use Authorization for CytoSorb use in critically ill COVID-19 patients with confirmed or imminent respiratory failure.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>在单中心试点试验中，Stockmann et al (1) 入选了 50 例重症患者，为需要去甲肾上腺素大于 0.2µg/(kg・min) 维持平均动脉压≥65 mmHg、CRP 大于 100 mg/L 且需要肾脏替代治疗 (KRT) 的急性肾损伤 (AKI) 3 期的患者 (2)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In the single-center pilot trial, Stockmann et al (1) enrolled 50 severely ill patients with need for norepinephrine greater than 0.2 µg/kg/min to maintain mean arterial pressure greater than or equal to 65 mm Hg, a CRP greater than 100 mg/L, and an acute kidney injury (AKI) stage 3 with need for kidney replacement therapy (KRT) (2).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>两组至血管麻痹好转的中位时间（主要终点）和病死率（次要终点）均相似。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>The median time to resolution of vasoplegia, the primary endpoint, was similar between both groups as was the secondary endpoint mortality rate.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>此外，其他次要结局参数（炎症标志物、儿茶酚胺需求以及不良事件的类型和发生率）在治疗组间相似。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Furthermore, other secondary outcome parameters (inflammatory markers, catecholamine requirements, and the type and rates of adverse events) were similar between the groups.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>由此，作者得出结论，在病情严重的 COVID-19 患者中，细胞因子吸附不能促进血管麻痹性休克的缓解。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Based on these data, the authors concluded that in severely ill COVID-19 patients, cytokine adsorption did not improve resolution of vasoplegic shock.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Stockmann 等 (1) 的研究中，细胞因子吸附未或成功的原因是什么？</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>What could have prevented the success of the intervention by cytokine adsorption in the study by Stockmann et al (1)?</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>细胞因子风暴的特征是循环细胞因子水平升高和免疫细胞过度活化，可由各种原因触发。一些作者认为，COVID-19 没有细胞因子风暴 (8)，而是肝细胞生长因子和 C-X-C 基序趋化因子配体 13 失调 (9)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Cytokine storm is characterized by elevated levels of circulating cytokines and immune-cell hyperactivation that can be triggered by various causes. Some authors argue that there is no cytokine storm in COVID-19 (8) but rather a dysregulation in hepatocyte growth factor and C-X-C motif chemokine ligand 13 (9).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>事实上，重度 COVID-19 患者中促炎性细胞因子的全身浓度不像其他原因导致的急性呼吸窘迫综合征患者所报告的那样高。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Indeed, systemic concentrations of pro-inflammatory cytokines in patients with severe COVID-19 are not as high as has been reported in patients with other causes of acute respiratory distress syndrome.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Stockmann 等人的研究结果 (1) 与另一项随机对照研究的结果一致，该研究在脓毒性休克和多器官衰竭患者中进行，CytoSorb 清除 IL-6，但这种清除对全身 IL-6 水平没有影响 (10)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>The study results by Stockmann et al (1) are in line with the results of another randomized controlled study in patients with septic shock and multiple organ failure in which CytoSorb removed IL-6, but the removal had no effect on systemic IL-6-levels (10).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>所以，像穿越加利利海猛烈的风暴出现神迹一样，因子风暴岂会轻易消退。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>So calming the storm, as one of the miracles of Jesus in a fierce storm sailing the Sea of Galilee, seems to be a challenging endeavor.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>其次，开始干预的时间可能太晚（指入院的时间以及疾病的状态）。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Second, intervention might have been initiated too late (referring to the time from admission as well as the state of the disease).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>实际上，CytoSorb 自进入 ICU 至开始治疗的中位时间为 15 天，对照组为 10 天。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Indeed, median time since ICU admission to the start of the treatment was 15 days for CytoSorb and 10 days in the control group.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>此外，入组患者不仅出现血管痉麻痹休克，还出现 AKI 和急性呼吸衰竭。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Further, the enrolled patients had not only vasoplegic shock but also AKI and acute respiratory failure.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>所有患者均需要有创机械通气，其中几乎一半患者需要体外膜肺氧合 (ECMO) 治疗。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>All patients required invasive mechanical ventilation and almost half of them required extracorporeal membrane oxygenation (ECMO) therapy.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>然而，从实践上来看，11 例患者作者在休克 24 小时内开始治疗，另外 12 例患者是在 24 小时内开始治疗。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Yet from a practical point of view, the authors managed to start the treatment within 24 hours of shock in 11 patients and in 12 patients treatment was started after 24 hours.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Cox 回归分析显示，尽管患者数量有限，但在 24 小时内开始治疗并未获益。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Cox regression analysis revealed no benefit in starting the therapy within 24 hours, although the number of patients was limited.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>联合 ECMO 开始治疗是否会得到不同的结果？</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Could a concomitant start of treatment along with ECMO therapy have made a difference?</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Supady et al (11) 该策略的最新数据未见获益。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>The recent data by Supady et al (11) see no benefit of this strategy.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>第三，已知 CytoSorb 可清除包括抗生素 (12) 和抗病毒药物（如 remdesivir (13)）在内的药物，因此治疗组可能考虑抗感染药物剂量不足。这尤其有意义，因为半数患者在研究入选时微生物学培养也为阳性。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Third, CytoSorb is known to remove drugs including antibiotics (12) and antivirals like remdesivir (13), so the treatment group might have suffered from underdosing of anti-infective drugs. This is especially relevant as half of the patients also had positive microbiological cultures at the time of study inclusion.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>尽管尚未获得治疗药物监测数据，但作者通过在 CytoSorb 组中每次更换过滤器时给予额外剂量的抗生素和瑞德西韦，来积极解决了这一问题。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Although therapeutic drug monitoring data are not available, the authors proactively addressed this point by giving an extra dose of antibiotics and remdesivir in the CytoSorb group with each filter change.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>最后，与既往试验一样，CytoSorb 不是单一的体外治疗，而是与 KRT 联合使用，这也可能产生积极或消极的影响。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Last, as in previous trials, CytoSorb was not used as a stand-alone extracorporeal treatment but rather was used in combination with KRT, which might also have had a positive or negative impact.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>这也将使 CytoSorb (14) 的未来研究难以解读为 KRT 本身，以及抗凝可能对患者结局产生影响 (15)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>This will also make future studies with CytoSorb (14) diﬃcult to interpret as KRT per se, as well as the anticoagulation might have an impact on patient outcome (15).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>在一项前瞻性、随机、开放标签研究中，Supady 等人 (11) 对 34 名接受 ECMO 治疗的 COVID-19 患者进行了研究，结果显示，无论是否使用 CytoSorb (11)，在 72 小时内均出现 IL-6 中位数下降。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In a prospective, randomized, open-label study, Supady et al (11) investigated 34 COVID-19 patients with ECMO therapy and showed that the median IL-6 drop over 72 hours occurred regardless of the use of CytoSorb (11).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>CytoSorb 组的 30 天病死率显著高于对照组 (11)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Thirty-day mortality was significantly higher in the CytoSorb group as compared with the control group (11).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>考虑到该研究，尽管在病死率上效能不足，但令人欣慰的是，Stockmann et al (1) 的研究显示无益但也未见潜在危害征象。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>With that study in mind, although underpowered for mortality, it is comforting that the study by Stockmann et al (1) did show an absence of benefit and no sign of potential harm.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>我们都希望不仅理解，而且可以通过降低促炎介质能很容易地解决炎症反应，但多项试验已证实这个想法是不对的。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Our collective hope that we not only understood but also could readily manipulate the inflammatory response by reducing pro-inflammatory mediators has been proven incorrect in several trials.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>我们现在认识到炎症反应包括通过促炎和抗炎介质网络传播的复杂机制。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>We now recognize the inflammatory response to include complex mechanisms propagated through networks of pro- and anti-inflammatory mediator.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>已证实，仅解决这一网络的一小部分，例如使用单一或甚至几种抗炎治疗，已证明是无效的。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Addressing only a small part of that network, such as with a single or even several anti-inflammatory treatment, has proven ineffective.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>同样，使用单一的非特异性吸附剂同样不太可能产生预期的有益作用。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Similarly, the use of a single nonspecific sorbent is equally unlikely to have a predictable salutary effect.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>此外，分子中和或物理吸附可能会触发意外甚至是不良的后果。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Furthermore, molecular neutralization or physical adsorption may trigger unanticipated and even adverse consequences.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>前瞻性对照试验设计之外，由于缺乏结果，应用 CytoSorb 的理由受到质疑。来自美国登记研究的数据 https://doi.org/10.3389/fmed.2021.773461 显示，1 年期内，接受 v-vECMO + CytoSorb 治疗的 52 例患者中，ICU30 天病死率为 17.3%(9/52)，90 天病死率为 26.9%(14/52)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Outside of the setting of controlled prospective trials, the rationale use of CytoSorb is questionable because of the lack of results. Data from a U.S. registry https://doi.org/10.3389/fmed.2021.773461
over a period of 1 year indicates in 52 patients receiving venovenous ECMO plus CytoSorb therapy an ICU mortality of 17.3% (9/52) on day 30 and 26.9% (14/52) on day 90.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>CytoSorb 耐受性良好，未报告任何设备相关不良事件。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>CytoSorb was well-tolerated without any devicerelated adverse events reported.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>值得注意的是，还需要接受 KRT 的患者的比例仅为 21%。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>It is of note the percentage of patients also requiring KRT was only 21%.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>5.7% 的患者进行了治疗性血浆置换。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Therapeutic plasma exchange was used in 5.7% of the patients.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>1921 年，丘吉尔的女儿玛丽戈尔德死于败血症。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Churchill’s daughter, Marigold, died of septicemia in 1921.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>一百年后，我们的目标是在疫情大流行的健康危机中拯救尽可能多的生命。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>One-hundred years later, we aim to save as many lives as possible amidst a pandemic health crisis.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>这就能说使用 Cytosorb 这类未得到验证的设备是正确的吗？</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Does this justify using untested devices like Cytosorb?</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>在大流行的早期阶段，这是一项还需要进一步探索的治疗选择。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In the early phase of the pandemic, it was among treatment options that needed to be explored.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>不幸的是，2020 年在德国，多个 “病毒性肺炎” 研究的（至少）449 名患者中，仅有少数接受了 CytoSorb 治疗。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Unfortunately, we do only have a small number of the (at least) 449 patients that received CytoSorb in Germany in 2020 for “viral pneumonia” in studies.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>纵观全球。许多其他体外操作情况也是如此。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>The same holds true for many extracorporeal procedures worldwide.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>更重要的是在感染性心内膜炎患者中使用 CytoSorb。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Even more relevant is the use of CytoSorb in patients with infective endocarditis.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>感染性心内膜炎的心脏手术患者使用血液吸附预防血管舒张性休克的机制探索和疗效调查试验，是 CytoSorb 最大的（每组约 140 例患者）随机对照公共资助研究 (16)。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>The Revealing Mechanisms and Investigating Eﬃciency Of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients with Infective Endocarditis trial, the biggest (about 140 patients per arm) randomized controlled, publicly funded study with the CytoSorb (16).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>该试验主要终点，改善序贯器官衰竭评估评分，和其他次要终点都未或成功。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>The trial failed to reach its primary endpoint, an improvement of the Sequential Organ Failure Assessment score, as well as other secondary endpoints.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>这是否会妨碍未来心血管外科医生使用该技术，以及保险公司的支付？</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Will this keep cardiovascular surgeons from using it and insurance companies paying for it in the future?</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>在循证医学时代，我们需要新的策略，为新的干预措施和设备建立一个坚实的数据库。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In the era of evidence-based medicine, we need new strategies to build a solid database for new interventions and devices.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>小公司需要有机会将新的（有时甚至是破坏性的）治疗方法推向市场。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Small companies need to get a chance to bring new—and at times disruptive therapies—to the market.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>在理想的世界中，他们自己无需为做成随机对照、效力足够的试验来获得足够的收益，而应该与卫健系统和医疗人员合作。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In an ideal world, they should not need to generate enough revenue for controlled randomized, adequately powered trials themselves but should partner with healthcare systems and healthcare providers.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>2020 年，德国保险公司支付了至少 6600 名患者 CytoSorb 治疗（有时是多个）的费用，但是没有将证据水平提高到现在的标准（图 1）。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>In 2020, insurance companies in Germany payed for (sometimes multiple) CytoSorb treatments in at least 6,600 patients without increasing the evidence level to today’s standards (Fig. 1).</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>正如温斯顿・丘吉尔所言，无论提出的治疗策略背后的机制有多吸引人，干预措施仍然必须得到设计良好且具有充分效力的临床试验的阳性结果来证实。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>To paraphrase Winston Churchill’s saying, no matter how intriguing the mechanisms behind a proposed therapeutic strategy might be, the intervention must still be substantiated by positive results of well designed and adequately powered clinical trials.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>应当赞美 Stockmann 等人（1），因为他们所做的工作令人钦佩 —— 而那些对 Stockmann 等人（1）的结果提出质疑的人应该拿出令人信服的前瞻性随机对照研究证据。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Stockmann et al(1) should be commended for doing precisely that— and those challenging the results by Stockmann et al (1) should present compelling evidence from prospective randomized studies.</p></section></div></div> <p><img src="/assets/img/image-20220722061629437.5b62d598.png" alt="image-20220722061629437" loading="lazy"></p> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>图 1. 2017 年至 2020 年间在德国至少接受过一次 Cytosorb 治疗的患者及其主要出院诊断 (Statistisches Bundesamt [Destatis],Wiesbaden,Germany)。尚不清楚每例患者的实际治疗次数。ARDS = 急性呼吸窘迫综合征，OPS-CODE = 手术和程序代码。</p></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"><p>Figure 1. Patients that received at least one Cytosorb treatment in Germany from 2017 to 2020 as well as their primary discharge diagnosis (Statistisches Bundesamt [Destatis], Wiesbaden, Germany). The actual number of treatments per patient is not known. ARDS = acute respiratory distress syndrome, OPS-CODE = Operation and Procedure Code.</p></section></div></div> <div class="tabs-component"><ul role="tablist" class="tabs-component-tabs"></ul> <div class="tabs-component-panels"><section aria-hidden="true" id="中" role="tabpanel" class="tabs-component-panel" style="display:none;"></section> <section aria-hidden="true" id="en" role="tabpanel" class="tabs-component-panel" style="display:none;"></section></div></div> <hr class="footnotes-sep"> <section class="footnotes"><ol class="footnotes-list"><li id="footnote1" class="footnote-item"><p>von Willebrand 因子：血管性血友病因子；ADAMTS13 是一种金属蛋白酶，主要在肝星状细胞中表达，特异性切割具有促血栓作用的大分子血管性血友病因子（von willebrand factor, VWF）多聚体。ADAMTS13 缺乏可导致超大分子 VWF 多聚体（UL-VWFM）持续存在于血管内，诱导血小板聚集，引发血栓性血小板减少性紫癜（TTP）。 <a href="#footnote-ref1" class="footnote-backref">↩︎</a></p></li></ol></section></div></div> <!----> <div class="page-edit"><div class="edit-link"><a href="https://github.com/seasideccm/seasideccm.github.io/edit/docs/docs/05.重症文献/18.细胞因子吸要废了吗？.md" target="_blank" rel="noopener noreferrer">编辑</a> <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></div> <!----> <div class="last-updated"><span class="prefix">上次更新:</span> <span class="time">2022/07/21, 23:04:12</span></div></div> <div class="page-nav-wapper"><div class="page-nav-centre-wrap"><a href="/pages/d30c19/" class="page-nav-centre page-nav-centre-prev"><div class="tooltip">在 COVID-19 相关呼吸衰竭患者中验证呼吸频率-氧合指数</div></a> <a href="/pages/0351a7/" class="page-nav-centre page-nav-centre-next"><div class="tooltip">危重儿童常用镇静镇痛评估方法</div></a></div> <div class="page-nav"><p class="inner"><span class="prev">
        ←
        <a href="/pages/d30c19/" class="prev">在 COVID-19 相关呼吸衰竭患者中验证呼吸频率-氧合指数</a></span> <span class="next"><a href="/pages/0351a7/">危重儿童常用镇静镇痛评估方法</a>→
      </span></p></div></div></div> <div class="article-list"><div class="article-title"><a href="/archives/" class="iconfont icon-bi">最近更新</a></div> <div class="article-wrapper"><dl><dd>01</dd> <dt><a href="/pages/2fbe62/"><div>
            器官血流压力自动调节的异质性和变异性
            <!----></div></a> <span class="date">06-05</span></dt></dl><dl><dd>02</dd> <dt><a href="/pages/314072/"><div>
            低血压对器官灌注和预后的异质性影响
            <!----></div></a> <span class="date">06-04</span></dt></dl><dl><dd>03</dd> <dt><a href="/pages/9f669f/"><div>
            自动调节的下限
            <!----></div></a> <span class="date">06-04</span></dt></dl> <dl><dd></dd> <dt><a href="/archives/" class="more">更多文章&gt;</a></dt></dl></div></div></main></div> <div class="footer"><div class="icons"><a href="mailto:2094558239@qq.com" title="发邮件" target="_blank" class="iconfont icon-youjian"></a><a href="https://github.com/seasideccm/" title="GitHub" target="_blank" class="iconfont icon-github"></a><a href="https://music.163.com/#/song?id=1324720213" title="听音乐" target="_blank" class="iconfont icon-erji"></a></div> 
  Theme by
  <a href="https://github.com/xugaoyi/vuepress-theme-vdoing" target="_blank" title="本站主题">Vdoing</a> 
    | Copyright © 2021-2022
    <span>SSCC | <a href="https://github.com/seasideccm/seasideccm.github.io/blob/main/LICENSE" target="_blank">MIT License</a></span></div> <div class="buttons"><div title="返回顶部" class="button blur go-to-top iconfont icon-fanhuidingbu" style="display:none;"></div> <div title="去评论" class="button blur go-to-comment iconfont icon-pinglun" style="display:none;"></div> <div title="主题模式" class="button blur theme-mode-but iconfont icon-zhuti"><ul class="select-box" style="display:none;"><li class="iconfont icon-zidong">
          跟随系统
        </li><li class="iconfont icon-rijianmoshi">
          浅色模式
        </li><li class="iconfont icon-yejianmoshi">
          深色模式
        </li><li class="iconfont icon-yuedu">
          阅读模式
        </li></ul></div></div> <div class="body-bg" style="background:url() center center / cover no-repeat;opacity:0.5;"></div> <!----> <!----></div><div class="global-ui"><div></div></div></div>
    <script src="/assets/js/app.1f0360bc.js" defer></script><script src="/assets/js/5.860c287a.js" defer></script><script src="/assets/js/36.7a8a83c9.js" defer></script>
  </body>
</html>
